Get started
BioGaia AB Class BBioGaia AB Class BBioGaia AB Class B

BioGaia AB Class B

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsTechnicalsForecastSeasonalsETFs

0GTN chart


Full chart

0GTN upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪10.96 B‬ SEK
Dividend yield (indicated)
6.47%
Price to earnings Ratio (TTM)
37.8
Basic EPS (TTM)
2.8 SEK
Net income (FY)
‪351.39 M‬ SEK
Revenue (FY)
‪1.42 B‬ SEK
Shares float
‪85.45 M‬
Beta (1Y)
0.45

Employees


Employees (FY)
225
Change (1Y)
+15 +7.14%
Revenue / Employee (1Y)
‪6.32 M‬ SEK
Net income / Employee (1Y)
‪1.56 M‬ SEK

About BioGaia AB Class B


Sector
Health Technology
Industry
Pharmaceuticals: Other
CEO
Theresa Agnew
Website
biogaia.com
Headquarters
Stockholm
Founded
1990
ISIN
SE0017769995
FIGI
BBG00NRVWCT8
BioGaia AB engages in the development, marketing, and sale of probiotic products. It operates through the following segments: Pediatrics, Adult Health, and Other. The Pediatrics segment sells drops, oral rehydration solutions, digestive health tablets, and also royalties pertaining to pediatric products. The Adult Health segment include gut health tablets, oral health products, and offers cultures as an ingredient in a licensee's dairy product. The Other segment consists royalties from the development projects, and revenue from packaging solutions. The company was founded by Jan Annwall and Peter Michael Rothschild in 1990 and is headquartered in Stockholm, Sweden.

Check out other big names from the same industry as 0GTN.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0GTN news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0GTN is 107.0 SEK — it has increased by 0.02% in the past 24 hours. Watch BioGaia AB Class B stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSIN exchange BioGaia AB Class B stocks are traded under the ticker 0GTN.
0GTN stock has fallen by −4.08% compared to the previous week, the month change is a 0.13% rise, over the last year BioGaia AB Class B has showed a −6.10% decrease.
We've gathered analysts' opinions on BioGaia AB Class B future price: according to them, 0GTN price has a max estimate of 130.00 SEK and a min estimate of 122.00 SEK. Watch 0GTN chart and read a more detailed BioGaia AB Class B stock forecast: see what analysts think of BioGaia AB Class B and suggest that you do with its stocks.
0GTN reached its all-time high on May 21, 2024 with the price of 136.5 SEK, and its all-time low was 17.7 SEK and was reached on Jan 29, 2010. View more price dynamics on 0GTN chart.
See other stocks reaching their highest and lowest prices.
0GTN stock is 1.84% volatile and has beta coefficient of 0.45. Track BioGaia AB Class B stock price on the chart and check out the list of the most volatile stocks — is BioGaia AB Class B there?
Today BioGaia AB Class B has the market capitalization of ‪10.96 B‬, it has increased by 2.84% over the last week.
Yes, you can track BioGaia AB Class B financials in yearly and quarterly reports right on TradingView.
BioGaia AB Class B is going to release the next earnings report on Oct 22, 2025. Keep track of upcoming events with our Earnings Calendar.
0GTN earnings for the last quarter are 0.87 SEK per share, whereas the estimation was 0.93 SEK resulting in a −6.12% surprise. The estimated earnings for the next quarter are 0.69 SEK per share. See more details about BioGaia AB Class B earnings.
BioGaia AB Class B revenue for the last quarter amounts to ‪405.00 M‬ SEK, despite the estimated figure of ‪391.30 M‬ SEK. In the next quarter, revenue is expected to reach ‪347.50 M‬ SEK.
0GTN net income for the last quarter is ‪87.91 M‬ SEK, while the quarter before that showed ‪80.20 M‬ SEK of net income which accounts for 9.61% change. Track more BioGaia AB Class B financial stats to get the full picture.
BioGaia AB Class B dividend yield was 1.74% in 2024, and payout ratio reached 56.09%. The year before the numbers were 1.88% and 52.52% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Oct 1, 2025, the company has 225 employees. See our rating of the largest employees — is BioGaia AB Class B on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BioGaia AB Class B EBITDA is ‪449.22 M‬ SEK, and current EBITDA margin is 30.56%. See more stats in BioGaia AB Class B financial statements.
Like other stocks, 0GTN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BioGaia AB Class B stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BioGaia AB Class B technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BioGaia AB Class B stock shows the neutral signal. See more of BioGaia AB Class B technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.